Hepatitis B Virus Program Update
Filed with ASX · · 2 pages · English
Earlier from Biotron
- Half Yearly Report and Accounts
- Successful Issue of the Entitlement Offer Shortfall
- Quarterly Activities/Appendix 4C Cash Flow Report
- Security Class Reinstatement to Quotation - BITO
- Rights Issue Close
Later from Biotron
- $525K R&D Rebate Received
- Sedarex First Milestone Met
- Resignation of Managing Director and Appendix 3Z
- Appointment of CEO and Executive Director
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron